Author

Elvira De Marino

Observed names: Elvira De Marino C, Elvira de Marino

Observed institutions: Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico

OpenAlex ID: A5069447231

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

2024 · Nicoletta Colombo, Elena Biagioli, et al. · The Lancet Oncology · 135

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial

2023 · Sandro Pignata, Sandro Pignata, et al. · The Lancet Oncology · 54

PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1

2013 · Giulia Pinton, Arcangela Gabriella Manente, et al. · Journal of Cellular and Molecular Medicine · 37

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

2023 · N. Colombo, A. Gadducci, et al. · British Journal of Cancer · 27

Conley Scale (CS) compared to Timed Up and Go Test (TUGT) in a Fall Prevention and Detection Project (FAPRE).

2015 · Elvira De Marino, Elvira De Marino, et al. · Journal of Clinical Oncology

A fall prevention and detection project: Preliminary results.

2014 · Elvira De Marino, Cristina Chesta, et al. · Journal of Clinical Oncology

Development of a side-effect self-monitoring HOME notebook (HNB): Results from a single institution experience.

2013 · Elvira de Marino, Sabrina Rossetti, et al. · Journal of Clinical Oncology

Works count: 9

Citation count: 252

H-index: 4

I10-index: 4